CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 84 enrolled
Drug / intervention
Ibuprofen arginine granules 400 mg +1 moredrug
Likely dose
Ibuprofen arginine granules 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05737069
NCT05737069Phase 1Completed

A Randomized, Open-label, Single-center, Single-dose, Two Treatment, Two-sequence, Two-period, Two-cohort, Two-way Crossover Bioequivalence Study of Two Ibuprofen Arginine Granules 400 mg Formulations Under Fasting and Fed Conditions in Chinese Healthy Adult Subjects

HALEON·interventional·Posted Feb 21, 2023·Updated Sep 19, 2024

In Brief

A Phase 1 clinical trial evaluating Ibuprofen arginine granules 400 mg and Ibuprofen arginine granules 400 mg (Spedifen) for Pain. Completed, enrolled 84 participants across 1 site.

Detailed Summary

The primary purpose of this study is to demonstrate the bioequivalence of two ibuprofen arginine granules 400 milligram (mg) formulations under fasting and fed conditions in Chinese healthy adult participants. The secondary purpose of this study is to assess the pharmacokinetic and safety profile of the test and reference preparations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedFeb 21, 2023
Enrollment StartApr 19, 2023
Primary CompletionMay 15, 2023
TodayJul 2, 2026
Enrollment to primary: 26 daysPosted 3.4 years ago

Interventions

Ibuprofen arginine granules 400 mgdrug

Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.

Ibuprofen arginine granules 400 mg (Spedifen)drug

Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.